Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, María Trojano, Angelo Bellinvia et al.|Brain|2020Cited by 90
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Pietro Annovazzi et al.|Journal of Neurology|2018Cited by 54
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7